{
    "2019-09-10": [
        [
            {
                "time": "",
                "original_text": "孙飘扬、陈启宇、吕明方往一个城墙口冲锋：中国药企进军世界前列的准备、挑战、时间",
                "features": {
                    "keywords": [
                        "孙飘扬",
                        "陈启宇",
                        "吕明方",
                        "中国药企",
                        "世界前列"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "A股明日风口：资本市场深改12条出台 外资限购令取消",
                "features": {
                    "keywords": [
                        "A股",
                        "资本市场深改",
                        "外资限购令取消"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融",
                        "资本"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "核心资产的下一站：大中型科技股",
                "features": {
                    "keywords": [
                        "核心资产",
                        "科技股"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "营收百亿药企大比拼：恒瑞、复星、上药",
                "features": {
                    "keywords": [
                        "营收百亿",
                        "恒瑞",
                        "复星",
                        "上药"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "PD-1市场价格战燃起 红海之中谁能掌握先机？",
                "features": {
                    "keywords": [
                        "PD-1",
                        "市场价格战",
                        "红海"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-09-08",
                "original_text": "【山证医药】医药行业周报（20190908）：建议持续关注医保目录谈判与“4+7”带量采购扩面",
                "features": {
                    "keywords": [
                        "医药行业",
                        "医保目录谈判",
                        "4+7带量采购"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "科技板块领跑A股 首只科技ETF规模激增近250%",
                "features": {
                    "keywords": [
                        "科技板块",
                        "A股",
                        "科技ETF",
                        "规模激增"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药行业周报:建议持续关注医保目录谈判与“4+7”带量采购扩面",
                "features": {
                    "keywords": [
                        "医药行业",
                        "医保目录谈判",
                        "4+7带量采购"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药行业半年报业绩综述:内部仍在分化,龙头业绩亮眼",
                "features": {
                    "keywords": [
                        "医药行业",
                        "半年报",
                        "业绩分化",
                        "龙头业绩"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}